On the other hand, this founder mutation has not been observed in Japanese individuals, resulting in the number of patients with pathogenic variants in CHEK2 in European populations (1.12% of breast cancer patients) to be threefold higher than in the Japanese population (0.38%) [58]. The gene discussed is CHEK2; the disease is breast carcinoma.